SG11201909856XA - Mesenchymal lineage precursor or stem cells with enhanced immunosuppression - Google Patents
Mesenchymal lineage precursor or stem cells with enhanced immunosuppressionInfo
- Publication number
- SG11201909856XA SG11201909856XA SG11201909856XA SG11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- stem cells
- mesenchymal lineage
- lineage precursor
- pct
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title abstract 4
- 210000000130 stem cell Anatomy 0.000 title abstract 4
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 3
- 208000024908 graft versus host disease Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241001006211 Silvius Species 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000001704 mesoblast Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901636A AU2017901636A0 (en) | 2017-05-04 | Method for treating Graft versus Host Disease (GVHD) | |
| AU2017901633A AU2017901633A0 (en) | 2017-05-04 | Potency assay for immunosuppression | |
| AU2018900551A AU2018900551A0 (en) | 2018-02-21 | Potency assay for immunosuppression II | |
| PCT/EP2018/061503 WO2018202853A1 (en) | 2017-05-04 | 2018-05-04 | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909856XA true SG11201909856XA (en) | 2019-11-28 |
Family
ID=62222586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909856X SG11201909856XA (en) | 2017-05-04 | 2018-05-04 | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200325450A1 (de) |
| EP (2) | EP4137562A1 (de) |
| JP (2) | JP7398959B2 (de) |
| KR (2) | KR20240056790A (de) |
| CN (1) | CN110753751A (de) |
| AU (1) | AU2018262788A1 (de) |
| BR (1) | BR112019022901A2 (de) |
| CA (1) | CA3062112A1 (de) |
| SG (1) | SG11201909856XA (de) |
| WO (1) | WO2018202853A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115361960A (zh) * | 2020-02-19 | 2022-11-18 | 迈索布拉斯特国际有限公司 | 用于治疗慢性移植物抗宿主病的方法 |
| JP2021136883A (ja) * | 2020-03-02 | 2021-09-16 | 株式会社ガイアバイオメディシン | 高活性ｎｋ細胞の処理方法 |
| CN112444479B (zh) * | 2021-02-01 | 2021-05-07 | 宁波大学 | 基于并行处理技术的单细胞质谱分析系统及方法 |
| CN113881707B (zh) * | 2021-10-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途 |
| WO2023119239A1 (en) * | 2021-12-23 | 2023-06-29 | Mesoblast International Sarl | Method of treating severe graft versus host disease |
| WO2024009226A1 (en) * | 2022-07-05 | 2024-01-11 | Mesoblast International Sarl | Cryopreserved intermediate and potency assay for same |
| WO2024036052A1 (en) | 2022-08-09 | 2024-02-15 | Exxonmobil Chemical Patents Inc. | Methods for preparing diphenylsilane bridged c1 symmetric catalysts and polymers made therefrom |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
| US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| DE4211351A1 (de) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
| CA2163129A1 (en) | 1993-05-17 | 1994-11-24 | Flossie Wong-Staal | Ribozyme gene therapy for hiv infection and aids |
| US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
| CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
| US6566051B1 (en) | 1999-01-15 | 2003-05-20 | Medtox Scientific, Inc. | Lateral flow test strip |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| JP4264348B2 (ja) | 2001-08-20 | 2009-05-13 | プロテオム システムズ リミテッド | 診断検査方法および装置 |
| CA2507415A1 (en) | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
| KR101446634B1 (ko) | 2005-04-12 | 2014-10-16 | 메소블라스트, 아이엔씨. | 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리 |
| EP1971679B1 (de) * | 2006-01-13 | 2013-04-10 | Osiris Therapeutics, Inc. | Mesenchymale stammzellen zur tnf-rezeptor-expression |
| ES2831259T3 (es) * | 2010-07-02 | 2021-06-08 | Mesoblast Inc | Tratamiento de la enfermedad de injerto contra huésped |
| US20120087933A1 (en) | 2010-10-08 | 2012-04-12 | Samson Tom | Enhanced msc preparations |
| KR20150016117A (ko) * | 2013-07-30 | 2015-02-11 | 코아스템(주) | 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물 |
| US10400218B2 (en) * | 2014-04-07 | 2019-09-03 | Mesoblast International Sarl | Stem cell composition |
| BR112017012911B1 (pt) * | 2014-12-23 | 2021-10-05 | Mesoblast International Sàrl | Método para tratamento de insuficiência cardíaca |
-
2018
- 2018-05-04 AU AU2018262788A patent/AU2018262788A1/en active Pending
- 2018-05-04 SG SG11201909856X patent/SG11201909856XA/en unknown
- 2018-05-04 EP EP22187395.3A patent/EP4137562A1/de active Pending
- 2018-05-04 KR KR1020247013202A patent/KR20240056790A/ko active Search and Examination
- 2018-05-04 JP JP2019560259A patent/JP7398959B2/ja active Active
- 2018-05-04 CN CN201880036997.2A patent/CN110753751A/zh active Pending
- 2018-05-04 BR BR112019022901A patent/BR112019022901A2/pt unknown
- 2018-05-04 US US16/607,293 patent/US20200325450A1/en active Pending
- 2018-05-04 WO PCT/EP2018/061503 patent/WO2018202853A1/en unknown
- 2018-05-04 EP EP18726345.4A patent/EP3619294A1/de active Pending
- 2018-05-04 KR KR1020197035053A patent/KR102660506B1/ko active IP Right Grant
- 2018-05-04 CA CA3062112A patent/CA3062112A1/en active Pending
-
2023
- 2023-10-05 JP JP2023173584A patent/JP2023174760A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7398959B2 (ja) | 2023-12-15 |
| EP4137562A1 (de) | 2023-02-22 |
| AU2018262788A1 (en) | 2019-11-14 |
| EP3619294A1 (de) | 2020-03-11 |
| KR20200003044A (ko) | 2020-01-08 |
| US20200325450A1 (en) | 2020-10-15 |
| CN110753751A (zh) | 2020-02-04 |
| KR20240056790A (ko) | 2024-04-30 |
| BR112019022901A2 (pt) | 2020-05-19 |
| JP2023174760A (ja) | 2023-12-08 |
| JP2020518260A (ja) | 2020-06-25 |
| WO2018202853A1 (en) | 2018-11-08 |
| CA3062112A1 (en) | 2018-11-08 |
| KR102660506B1 (ko) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |